Form 483

Danbury Pharma, LLC Form 483, 2012-03-29

FDA issued a Form 483 to Danbury Pharma, LLC on 2012-03-29 with 6 public-safe observations.

483· Form 483 issued6 observations

Danbury Pharma, LLC · Farmingdale, United States · Issued March 29, 2012

Overview

  • 6 public-safe observations are available for this inspection.
  • 6 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

29 Mar 2012
21 CFR 111.20(c)(7)

Physical plant - separate areas - holding

Cited by Meredith P Soehl

29 Mar 2012
21 CFR 111.105(i)

Quality control - required operations product complaints

Cited by Meredith P Soehl

29 Mar 2012
21 CFR 111.110(c)

Quality control operations - tests, examinations; results

Cited by Meredith P Soehl

29 Mar 2012
21 CFR 111.255(c)

Batch record - follow master

Cited by Meredith P Soehl

29 Mar 2012
21 CFR 111.260(l)(3)

Batch record - approved, released, rejected; batch

Cited by Meredith P Soehl

Inspected site

DPDanbury Pharma, LLCFarmingdale, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 111.105(i)Cited across public-safe Form 483 observations1x
21 CFR 111.110(c)Cited across public-safe Form 483 observations1x
21 CFR 111.20(c)(7)Cited across public-safe Form 483 observations1x
21 CFR 111.255(c)Cited across public-safe Form 483 observations1x
21 CFR 111.260(l)(3)Cited across public-safe Form 483 observations1x
21 CFR 111.303Cited across public-safe Form 483 observations1x

Full 483 report

Get the verbatim text of all 6 observations

Every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere